Navigation Links
Coherus Announces CHS-1420 (Investigational Adalimumab Biosimilar) Meets Primary Endpoint In Pivotal Pharmacokinetic Clinical Study
Date:8/14/2014

in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team's collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development.  Coherus' commercialization partnerships include global pharmaceutical companies in Europe, Asia and Latin America.

Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access.  For additional information, please visit www.coherus.com.

Coherus BioSciences Contact
Beth Jimison
(650) 649-3526
bjimison@coherus.com

Logo - http://photos.prnewswire.com/prnh/20120507/SF01448LOGO


'/>"/>
SOURCE Coherus BioSciences
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Coherus anuncia início do estudo Fase 3 do CHS-0214 (Biossimilar Investigativo do Etanercept) em psoríase crônica em placas (RaPsOdy)
2. Coherus Announces Initiation Of Phase 3 Trial Of CHS-0214 (Investigational Etanercept Biosimilar) In Chronic Plaque Psoriasis (RaPsOdy)
3. Coherus Biosciences Invited to Present at 2014 J.P. Morgan Annual Healthcare Conference
4. Coherus Biosciences als Präsentator zur J.P. Morgan Annual Healthcare Conference 2014 eingeladen
5. Coherus anuncia que CHS-0214 (biosimilar etanercept propuesto) supera punto final primario en decisivo estudio clínico farmacocinético
6. Coherus Announces CHS-0214 (Proposed Etanercept Biosimilar) Meets Primary Endpoint In Pivotal Pharmacokinetic Clinical Study
7. Echo Therapeutics, Inc. Announces Second Quarter 2014 Financial Results and Provides Business Update
8. Edison Nation Medical Announces Innovation Search To Improve Hazardous Waste Disposal in Hospitals & Healthcare Facilities
9. NW BIO ANNOUNCES PRICING OF $17.5 MILLION OFFERING OF CONVERTIBLE NOTES
10. Vermillion Announces Additions to Commercial Management Team
11. Immune Pharmaceuticals Announces Second Quarter 2014 Financial Results and Provides Update on Bertilimumab Commencement of Phase II Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 2014  Come fall, many children, teenagers, and even ... want to be for Halloween. And, a number of ... contact lenses bought without a prescription. Halloween, ... purchase and wear contact lenses without a prescription. According ... consumer survey, 17 percent of Americans have worn ...
(Date:9/30/2014)... Sept. 30, 2014 CytRx Corporation (NASDAQ: ... development company specializing in oncology, today announced the ... evaluating aldoxorubicin compared to topotecan in subjects with ... relapsed or were refractory to prior chemotherapy. Aldoxorubicin ... agent, doxorubicin. CytRx has received Orphan Drug Designation ...
(Date:9/29/2014)... and DUBLIN , Sept. ... or the "Company"), a biotechnology company pioneering the manufacturing ... of innovative therapies for cancer, HIV/AIDS, opportunistic infections and ... its shareholders from CEO Noreen Griffin The letter follows: ... (the "Company" or "TNIB") received a number of calls ...
Breaking Medicine Technology:The Spooky Truth: What You Need To Know About Contact Lens Hygiene 2The Spooky Truth: What You Need To Know About Contact Lens Hygiene 3CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 2CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 3CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 4CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 5TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Cytocom Dividend 2TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Cytocom Dividend 3TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Cytocom Dividend 4TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Cytocom Dividend 5TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Cytocom Dividend 6TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Cytocom Dividend 7TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Cytocom Dividend 8
... 15 Tolerx, Inc., a,biopharmaceutical company engaged in ... treatment of immune-mediated diseases, announced today,the successful completion ... a novel,humanized anti-CD4 monoclonal antibody (MAb), in subjects ... study was designed to,assess the safety, tolerability, and ...
... System Runs ,Heart Model of the Future, ... To Insight, SUNNYVALE, Calif., Jan. 15 In the quest ... Montreal (UdM) have run the largest mathematical simulation of a heart,ever ... system from SGI (Nasdaq: SGIC ). The new UdM model ...
Cached Medicine Technology:Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus 2Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus 3Universite de Montreal Researchers Simulate World's Largest Heart Model Using SGI Technology 2Universite de Montreal Researchers Simulate World's Largest Heart Model Using SGI Technology 3Universite de Montreal Researchers Simulate World's Largest Heart Model Using SGI Technology 4
(Date:9/30/2014)... 2014 Julie Kuriakose, MD; ... , will discuss how restaurants can become more allergy-friendly ... dietary restrictions at the 2014 Allergy Eats Food ... October 21 in New York City. , “I’m extremely ... to such an engaged industry audience. As food allergies ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 In ... well as better data capture and management functions ... ClinCapture electronic data capture (EDC) system. ClinCapture offers ... ability to easily manage clinical trial data and ... cement Synergy’s position as the leading clinical research ...
(Date:9/30/2014)... From October 12-15, MMS, Inc. (Medical ... SHSMD Connections Annual Conference in San Diego, California. ... Development (SHSMD) is proud to host the event of ... and strategic planning professionals in San Diego this fall: ... conference is a four-day event designed to equip ...
(Date:9/30/2014)... Bibliomotion is proud to announce the release of ... Social Age by Frank Guglielmo and Sudhanshu ... authors apply their leadership coaching experience to introduce Social Leadership ... and behaviors that leaders must adopt in order to thrive ... read a review of The Social Leader in Dialogue Reviews. ...
(Date:9/30/2014)... JACKSON, Tenn. (PRWEB) September 30, 2014 ... Oct. 4, from 10 a.m. to 2 p.m. at ... Pinson). Woodmen of the World sponsors this family-oriented festival, ... free, and the festival will feature a car show, ... climbing wall, hayride and children’s games. Also, Lightning McQueen ...
Breaking Medicine News(10 mins):Health News:Hudson Allergy’s Dr. Julie Kuriakose to Speak at Prestigious Food Allergy Conference in New York City 2Health News:Hudson Allergy’s Dr. Julie Kuriakose to Speak at Prestigious Food Allergy Conference in New York City 3Health News:Synergy Research Group Opts for Clinovo 2Health News:Synergy Research Group Opts for Clinovo 3Health News:MMS, Inc. (Medical Marketing Service) to Attend the 2014 SHSMD Connections Annual Conference in October 2Health News:The Social Leader: new Bibliomotion book redefines leadership for the Social Age 2Health News:The Social Leader: new Bibliomotion book redefines leadership for the Social Age 3Health News:The Social Leader: new Bibliomotion book redefines leadership for the Social Age 4Health News:The Social Leader: new Bibliomotion book redefines leadership for the Social Age 5Health News:The Social Leader: new Bibliomotion book redefines leadership for the Social Age 6
... coverage and other problems persist, analysis shows, , WEDNESDAY, July ... access to prescription drug coverage has ballooned since Medicare,s Part ... new analysis finds, yet seniors, ability to pay for needed ... rising drug plan costs. , "Based on nearly four years ...
... in the regulation of cell death has been identified ... led them to recommend caution when drugs called IAP ... liver conditions. , A team led by Professor Andreas ... has found that XIAP (X-chromosome-linked inhibitor of apoptosis protein) ...
... , Presidential Health Advisor , s Writings Support ... DALLAS, July 22 On the cusp of President Obama,s news conference tonight, ... care reform plan may result in denying care to a significant number of ... Administration does not consider doctors the best judges of the type of health ...
... WEDNESDAY, July 22 (HealthDay News) -- One part of the ... when deadly plaque builds up, but two other sections don,t, ... Wake Forest University Baptist Medical Center have found. , ... and left carotid arteries expands by 11 percent, on average, ...
... , , LANTANA, Fla., July ... (IHPA), announced today the launching of the , ... Get the Number , campaign is an ... for when buying storm and hurricane protection," Johnston said. "Consumers ...
... , , OAK BROOK, ... gastroenterologists, gastroenterology nurses and gastroenterology fellows, announces enhanced site content ... , , NAAP describes the ... of a physician, or by a physician or nurse other ...
Cached Medicine News:Health News:Medicare Drug Plan Still Needs Work 2Health News:Medicare Drug Plan Still Needs Work 3Health News:Critical link in cell death pathway revealed 2Health News:NCPA: White House Has Ideas on How to Ration Health Care 2Health News:Carotid Artery Sections React Differently to Plaque 2Health News:IHPA Launches Consumer Awareness Campaign for Hurricane Protection 2Health News:IHPA Launches Consumer Awareness Campaign for Hurricane Protection 3Health News:SedationFacts.org Presents Content on Policies and Conditions Regarding Alternative Methods for the Administration of Propofol 2Health News:SedationFacts.org Presents Content on Policies and Conditions Regarding Alternative Methods for the Administration of Propofol 3Health News:SedationFacts.org Presents Content on Policies and Conditions Regarding Alternative Methods for the Administration of Propofol 4
0.25 mm diameter textured tip with protective guard....
... for perfect focus where it's needed - ... along with Keeler's wide angle light beam ... patient's pupil size, you will see the ... technology provides a longer life battery and ...
... for perfect focus where it's needed - ... along with Keeler's wide angle light beam ... patient's pupil size, you will see the ... technology provides a longer life battery and ...
... individually adjusted for perfect focus where it's ... paper. This, along with Keeler's wide angle ... whatever the patient's pupil size, you will ... view. Lithium-ion technology provides a longer life ...
Medicine Products: